Cure­Vac claims de­lay in Ger­man court over al­leged in­fringe­ment of its Covid-19 vac­cine by BioN­Tech a sign in its fa­vor

Cure­Vac is ex­pect­ing good news in its patent in­fringe­ment cas­es for com­po­nents of its Covid-19 vac­cine against Pfiz­er part­ner BioN­Tech in Ger­many af­ter a court post­poned pro­ceed­ings on four cas­es, the com­pa­ny an­nounced Thurs­day.

Cure­Vac said that courts in Ger­many on­ly sus­pend pro­ceed­ings if they be­lieve there has been in­fringe­ment on patent­ed prop­er­ty.

“Giv­en the par­tic­u­lar­i­ties of Ger­man patent law, where patent in­fringe­ment and va­lid­i­ty are ad­ju­di­cat­ed by sep­a­rate pro­ceed­ings, the sus­pen­sion of pro­ceed­ings un­til the va­lid­i­ty of in­tel­lec­tu­al prop­er­ty rights has been de­ter­mined was ex­pect­ed,” Cure­Vac CEO Alexan­der Zehn­der said in a state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER